CVS Health Corp vs STMicroelectronics NV — how do they compare? CVS Health Corp trades at $86.75 (market cap $112.29B), while STMicroelectronics NV trades at $52.05 (market cap $48.14B). The key difference: CVS Health Corp is far larger — about 2.3× STMicroelectronics NV's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and STMicroelectronics NV for 66 Days on average.
| CVS | STM | |
|---|---|---|
Market Cap | $112.29B | $48.14B |
Volume | 7,763,676 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $110.60 | $79.91 |
52-Week Low | $70.08 | $21.20 |
Typical Hold Time | 83 Days | 66 Days |
Enterprise Value | $174.64B | $45.66B |
Dividend Yield | 3.03% | 0.68% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
STM trades at $56.18, down 4.33% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining revenue from $17.3B in 2023 to $11.8B in 2025 and negative net income margin of -0.39%, though Q2 2026 earnings beat expectations. Analyst consensus is bullish with a $77.31 price target, and recent news highlights AI data-center revenue potential exceeding $2B by 2027.
Outlook is cautiously optimistic driven by AI and automotive growth catalysts, but risks include profitability challenges and competitive pressures. The stock offers 37% upside to consensus target if execution improves, though investors should monitor margin recovery and debt levels amid volatile semiconductor cycles.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →